VivoSeq
Gastroenterology

GERD

1

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

GERD is an early-stage landscape with 1 program across 4 companies. The most active players are Dexcel Pharma Technologies Ltd., AstraZeneca, Takeda.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

D

Dexcel Pharma Technologies Ltd.

1 program

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalEisai logo

Eisai

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

Omeprazole

Dexcel Pharma Technologies Ltd.

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

16

clinical trials

Completed10 · 63%
Unknown status2 · 13%
Recruiting2 · 13%
Active, not recruiting1 · 6%
Not yet recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

Alginate vs Sucralfate for GERD Symptomatic Relief
Recruiting·—·Phase 2/3·NCT07310927·140 enrolled
Pathophysiological Evidence Driven Management of GERD in Neonatal ICU Infants: Randomized Controlled Trial
Recruiting·NNationwide Children's Hospital·Preclinical·NCT06114836·369 enrolled
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
Active, not recruiting·MMicrobiome Health Sciences·Phase 2·NCT05556824·247 enrolled
Laparoscopic Toupet Fundoplication With or Without Preoperative Esophageal Manometry in Patients With GERD and Hiatal Hernia
Not yet recruiting·MMcMaster University·Preclinical·NCT07659080·96 enrolled
Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD
Completed·VVA Greater Los Angeles Healthcare System·Phase 4·NCT00304421·23 enrolled
Study Using Esomeprazole as a Diagnostic Test for GERD in Patients With NCCP
Completed·NNational University Hospital, Singapore·N/A·NCT00786695·60 enrolled
Symptom Adapted Therapy in GERD Patients
Completed·AstraZeneca logoAstraZeneca·Phase 4·NCT00343161·441 enrolled
Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD
Completed·DDigestive & Liver Disease Specialists·Phase 4·NCT00295685·50 enrolled
Response to Supplement and Placebo in GERD
Completed·—·N/A·NCT01915173·24 enrolled
Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients
Completed·RReckitt Benckiser Healthcare (UK) Limited·Phase 3·NCT01872897·45 enrolled
Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)
Completed·Takeda logoTakeda·Phase 2·NCT02743949·256 enrolled
Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients
Completed·AstraZeneca logoAstraZeneca·Phase 4·NCT00444275·3,029 enrolled
Maintenance Intermittent Therapy for Symptomatic GERD Patients
Completed·Eisai logoEisai·Phase 2·NCT00165841·200 enrolled
Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD
Completed·RRussian Academy of Medical Sciences·Phase 4·NCT01882088·36 enrolled
Comparison of the Efficiency of Two Different PPI Formula in Atypical GERD
Unknown status·TTaipei Veterans General Hospital, Taiwan·N/A·NCT03418337·120 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)